In this week’s blog, our Founder and Medical Director, Mr Guy Slater, addresses growing public concern about a potential link between GLP-1 medications and pancreatitis. With headlines often painting an alarming picture, Guy provides a clear, evidence-based overview of the real risks, the role of gallstones, and why GLP-1 therapies remain a safe and powerful tool in managing obesity and type 2 diabetes.
Media headlines vs medical reality
Recent headlines have raised concerns about a possible link between GLP-1 medications like Mounjaro (tirzepatide) and Ozempic (semaglutide) and pancreatitis, a potentially serious condition. These reports can sound alarming, but it’s important to put them into context.
Extensive clinical trials and real-world evidence continue to support the safe and effective use of GLP-1 drugs for weight loss and diabetes, when prescribed appropriately.
Healthcare regulators, including the UK’s MHRA and NICE, have carefully reviewed the evidence and continue to endorse GLP-1 receptor agonists, provided patients and prescribers remain aware of the very small potential risk and take appropriate precautions.
What is pancreatitis?
Pancreatitis means inflammation of the pancreas, an organ that lies behind the stomach in the upper abdomen. The pancreas regulates blood sugar and produces enzymes to digest food.
Pancreatitis typically causes sudden upper abdominal pain (often radiating to the back), along with nausea, vomiting, fever, and a racing pulse.
Most cases are mild and resolve with supportive treatment like IV fluids, pain control, and fasting. However, severe pancreatitis can lead to organ failure or death, which is why prompt care is essential.
How common is pancreatitis – and is it caused by GLP-1s?
Pancreatitis affects around 56 people per 100,000 annually. If 1 million people in the UK are on GLP-1 therapy, we’d expect around 560 cases yearly — or about 50 a month — regardless of medication.
This doesn’t mean GLP-1 medications cause pancreatitis. It means some patients already had or were going to develop it anyway.
So far, large studies have not shown a consistent or significant increase in pancreatitis risk with semaglutide, tirzepatide, or other GLP-1s compared to placebo.
Gallstones: the more likely cause
In the UK, gallstones are the leading cause of acute pancreatitis, followed by alcohol. Gallstones can block ducts and trigger pancreatic inflammation.
People who are female, over 40, overweight, or experiencing rapid weight loss (all common characteristics of those prescribed GLP-1 injections) are more likely to develop gallstones.
Weight loss itself — whether from diet, bariatric surgery, or GLP-1 medications — is a risk factor for gallstones, not necessarily the medicine.
Reassuringly, if you’ve had your gallbladder removed (cholecystectomy), your risk of GLP-1 related pancreatitis is likely reduced.
Can GLP-1 drugs directly cause pancreatitis?
Some medications (e.g., thiazide diuretics, corticosteroids, antibiotics) can directly trigger pancreatitis. GLP-1 receptor agonists do not appear to act in this way.
While rare cases have been reported, studies like SURMOUNT-1 show similar pancreatitis rates in those receiving placebo. Regulatory guidance still recommends stopping the drug if pancreatitis is suspected, but there’s no strong evidence of a direct link.
Why the benefits of GLP-1 medications outweigh the risks
GLP-1 drugs like Ozempic and Mounjaro offer life-changing health outcomes:
10–20% weight loss
Better control of type 2 diabetes
Lower blood pressure and cholesterol
Reduced risk of heart disease, stroke, and kidney damage
For most patients, these benefits outweigh the very low and uncertain risk of pancreatitis.
What can patients do to minimise their risk?
You can take practical steps to reduce the already low risk of pancreatitis from GLP-1 medications:
Know the signs: Seek urgent care for severe upper abdominal pain, vomiting, or fever.
Discuss history: Inform your doctor if you’ve had gallstones, pancreatitis, or alcohol misuse.
Stay hydrated: This supports pancreatic and digestive health.
Lose weight slowly: Gradual weight loss and proper GLP-1 titration help reduce gallstone formation.
Review your medications: Avoid combining with drugs known to trigger pancreatitis.
In summary
Concerns about GLP-1-induced pancreatitis are understandable. But the evidence shows:
Pancreatitis is rare
Most cases are not caused by GLP-1s
Gallstones and rapid weight loss are more likely culprits
The benefits of GLP-1 therapy for obesity and diabetes are significant
With proper supervision, GLP-1 medications remain safe and effective tools in managing chronic metabolic disease.
